Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed · Phase 3 · Has a placebo group

Conditions studied: Cataract, Inflammation, Surgery

In brief

The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Key facts

Study ID
NCT01591161
Run by
Bausch & Lomb Incorporated
People needed
369
Starts
2012-07-01
Expected to finish
2013-07-01
Last updated by the study team
2020-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.